Caxton Associates (New York)’s Tarsus Pharmaceuticals TARS Stock Holding History

Caxton Associates (New York)’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$918K	Buy	+16,588	New	+$753K	0.03%	232

Other funds holding TARS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Caxton Associates (New York)'s TARS Position: Q4 2024 in Review

Caxton Associates (New York) opened a new position in Tarsus Pharmaceuticals (TARS) in Q4 2024: 16,588 shares worth $918K. The stake represents 0.03% of the portfolio and ranks #232 among its holdings.

195 funds tracked by Wall St. Rank hold TARS as of Q4 2024.

Caxton Associates (New York) held 16,588 shares of Tarsus Pharmaceuticals worth $918K as of Q4 2024.
Tarsus Pharmaceuticals was a new Caxton Associates (New York) position in Q4 2024.
Tarsus Pharmaceuticals made up 0.03% of Caxton Associates (New York)'s portfolio in Q4 2024, its #232 holding.
195 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.